Terns Pharmaceuticals Inc. (TERN) Launches $75M Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Google defeats US bid to force ad tech sale
Terns Announces Proposed Public Offering
December 19, 2022 4:31 PM ESTFOSTER CITY, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. In addition, Terns expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.... More
